Moderna R&D Day Highlights Progress and Strategic Priorities
Sep 12, 2024 · Looking ahead to 2026-2028, Moderna will expand its commercial portfolio with first-in-class vaccines and therapeutics to address non-respiratory diseases, including cytomegalovirus, norovirus, propionic acidemia, methylmalonic acidemia, and melanoma.
Moderna to Host Investor Event - R&D Day and Business Updates
Aug 30, 2023 · CAMBRIDGE, MA / ACCESSWIRE / August 30, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - RD Day and Business Updates at 1:00 p.m. ET on Wednesday, September 13, 2023.
Novartis upgrades mid-term sales growth guidance, showcases its ...
Nov 28, 2023 · Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day. Ad hoc announcement pursuant to Art. 53 LR. Basel, November 28, 2023 — Novartis executives are meeting investors and analysts today at an event in London, U.K., to showcase the company’s ‘pure play ...
The mRNAge is here. - Moderna
At R&D Day, we announced that its updated seasonal flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial, and additional Phase 1/2 data demonstrated higher titers than comparators.
Novartis R&D day spotlights attractive growth profile, …
Dec 2, 2021 · New announcements at R&D Day 2021: Cosentyx, our largest medicine by sales, showed topline results in moderate to severe hidradenitis suppurativa (HS), a potential new indication.
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
Sep 8, 2022 · CAMBRIDGE, MA / ACCESSWIRE / September 8, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced advances across its portfolio of mRNA programs presented at the Company's annual R&D Day.
Novartis R&D day spotlights attractive growth profile, underpinned …
Basel, December 2, 2021 — Novartis today holds an investor event to provide a comprehensive overview of the company’s progress in advancing its industry-leading R&D engine.
D Day Highlights Modernaâ
At Moderna’s sixth annual Research & Development Day, presentations from CEO Stéphane Bancel, President Stephen Hoge, M.D., and Moderna clinical team leaders discussed the organization’s advances across a portfolio of mRNA programs. The 2022 R&D Day sessions focused on Phase 3 trials and programs currently dosing in their target patient ...
Novartis R&D day spotlights attractive growth profile,
Feb 12, 2021 · New announcements at R&D Day 2021: Cosentyx, our largest medicine by sales, showed topline results in moderate to severe hidradenitis suppurativa (HS), a potential new indication.
IR Insights: Highlighting Progress and Strategic Priorities at R&D Day
Sep 13, 2024 · At our annual R&D Day, Moderna announced program and financial updates demonstrating progress and strategic prioritization of its mRNA pipeline.
- Some results have been removed